Beta
Trial Radar KI
Die klinische Studie NCT06686524 für Dermatomyositis, Juvenile, Dermatomyositis ist offene rekrutierung. In der Kartenansicht des Klinische Studien Radar und den KI-Entdeckungstools finden Sie alle Details. Oder stellen Sie hier Ihre Fragen.
Eine Studie entspricht den Filterkriterien
Kartenansicht
Zurück zur Suche

Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocytes (UCAR-T) for the Treatment of Refractory Juvenile Dermatomyositis (RJDM) Phase 1 18 Zelltherapie Offene Studie

Offene Rekrutierung
Die Details der klinischen Studie sind hauptsächlich auf Englisch verfügbar. Trial Radar KI kann jedoch helfen! Klicken Sie einfach auf 'Studie erklären', um die Informationen zur Studie in der ausgewählten Sprache anzuzeigen und zu besprechen.
Die klinische Studie NCT06686524 untersucht Behandlung im Zusammenhang mit Dermatomyositis, Juvenile, Dermatomyositis. Diese interventionsstudie der Phase 1 hat den Status offene rekrutierung und startete am 11. November 2024. Es ist geplant, 18 Teilnehmer aufzunehmen. Durchgeführt von Chongqing Precision Biotech Co., Ltd wird der Abschluss für 10. November 2027 erwartet. Die Daten von ClinicalTrials.gov wurden zuletzt am 13. November 2024 aktualisiert.
Kurzbeschreibung
This study is an open-label, single-arm, dose-escalation trial primarily designed to evaluate the safety and efficacy of a universal CAR-T cell therapy targeting CD19 in the treatment of patients with RJDM. Additionally, the study aims to characterize its pharmacokinetic and pharmacodynamic properties, explore its role in immune system reconstitution, and assess long-term survival benefits.
Ausführliche Beschreibung
This study adopts the "3+3" design, with a total of three dosage groups (1 × 107/kg, 3 × 107/kg, 6 × 107/kg). The study will start from the low dose group. Only when the present dose group has completed enrollment and no DLT has been observed, the study could escalate to the next dose group based on the evaluation of efficacy and cell kinetic data. If no DLT is observed even in the highest dose group, the escalation ...Mehr anzeigen
Offizieller Titel

Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocytes (UCAR-T) for the Treatment of Refractory Juvenile Dermatomyositis (RJDM)

Erkrankungen
Dermatomyositis, JuvenileDermatomyositis
Weitere Studien-IDs
  • PBC081
NCT-Nummer
NCT06686524
Studienbeginn (tatsächlich)
2024-11-11
Zuletzt aktualisiert
2024-11-13
Studienende (vorauss.)
2027-11-10
Geplante Rekrutierung
18
Studientyp
Interventionsstudie
PHASE
Phase 1
Status
Offene Rekrutierung
Stichwörter
Dermatomyositis
CD19
UCAR-T
Universal CAR-T
Primäres Ziel
Behandlung
Zuteilungsmethode
Nicht zutreffend
Interventionsmodell
Einarmige Studie
Verblindung
Keine (offene Studie)
Studienarme/Interventionen
Teilnehmergruppe/StudienarmIntervention/Behandlung
ExperimentellAnti-CD19 UCAR-T cells
Anti-CD19 UCAR-T cells
A single infusion of CD19 UCAR-T cells will be administered intravenously after lymphodepletion chemotherapy.
Hauptergebnismessungen
ErgebnismessungBeschreibung der MessungZeitrahmen
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
The incidence of adverse events after CAR-T cell infusion was assessed by CTCAE, version 5.0.
28 dyas
Total improvement score (TIS) after anti-CD19 UCAR-T cells infusion.
The total improvement score between 0-100 also corresponds to the degree of improvement, with higher improvement scores indicating greater improvement.
6 months
Disease Activity Score (DAS) after anti-CD19 UCAR-T cells infusion.
Including musculoskeletal system score and skin mucosal score, with a total score of 20 points. The higher the score, the higher the disease activity
6 months
Changes of myositis specific antibody levels and serum muscle enzyme levels after anti-CD19 UCAR-T cells infusion.
6 months
Improvement in muscle inflammation infiltration by MRI after anti-CD19 UCAR-T cells infusion.
6 months
Childhood Myositis Assessment Scale (CMAS) score after anti-CD19 UCAR-T cells
The total score is 52 points, the lower the score, the weaker the muscle strength and the more severe the disease.
6 months
Nebenergebnismessungen
ErgebnismessungBeschreibung der MessungZeitrahmen
Cmax of anti-CD19 UCAR-T cells [Cell dynamics]
1 month
Tmax of anti-CD19 UCAR-T cells [Cell dynamics]
1 month
AUCs of anti-CD19 UCAR-T cells [Cell dynamics]
1 month
Changes of myth enzyme after anti-CD19 UCAR-T cells
1 year
Teilnahme-Assistent
Eignungskriterien

Zugelassene Altersgruppen
Kind, Erwachsene, Ältere Erwachsene
Mindestalter
5 Years
Zugelassene Geschlechter
Alle

  • (1) Age ≥ 5 years old;

  • (2) Diagnosis of juvenile dermatomyositis (JDM) according to Bohan and Peter criteria;

  • (3) Meeting the classification criteria for RJDM, and meeting condition ① and any one of ② to ⑤ conditions:

    • Intolerance or inadequate response to glucocorticoids (prednisone 1-2mg/kg/d or equivalent dose of other hormones) and at least two immunosuppressants, with hormone therapy lasting for at least 6 months;

      • Rapid progression of the disease and/or involvement of organs such as lungs, heart, and gastrointestinal tract;

        • Calcification of subcutaneous or muscular and articular tissues;

          • Repeated skin rashes or ulcers;

            • Repeated or persistent muscle weakness (muscle magnetic resonance imaging indicating widespread, diffuse edema or a Children's Myositis Assessment Scale (CMAS) score < 48, and at least two abnormal results among the following five core measurement indicators: Physician's Global Assessment (PhGA) ≥ 2cm, Patient's Global Assessment (PtGA) ≥ 2cm, Disease Activity Score (DAS) ≥ 2 points, Child Health Assessment Questionnaire (C-HAQ) total score ≥ 0.25 points, and muscle enzyme level > 1.5 times the upper limit of normal (ULN));

  • (4)Patients with immune-mediated necrotizing myopathy who are positive for SRP or HMGCR antibodies meet the criteria for RJDM and can be directly included;

  • (5) Basic normal function of important organs:

    • Cardiac function: Left ventricular ejection fraction (LVEF) ≥55%, with no significant abnormalities observed in the electrocardiogram;

      • Renal function: eGFR ≥ 30mL/min/1.73m2;

        • Liver function: AST and ALT ≤3.0 ULN, total bilirubin ≤2.0×ULN (excluding those caused by primary diseases);

          • Pulmonary function: SpO2 ≥92%;

  • (6) Female subjects of childbearing age have a negative result in the urine pregnancy test and agree to take effective contraceptive measures during the trial until one year after infusion;

  • (7) The patient or their guardian agrees to participate in this clinical trial and signs an informed consent form, indicating their understanding of the purpose and procedures of the clinical trial and their willingness to participate in the study.

Subjects meeting any of the following criteria will be excluded from this trial:

  • (1) Previously received CAR-T cell therapy (except for those whose safety risks have been judged as eliminated by the investigator);
  • (2) Accompanied by primary immunodeficiency disease or severe secondary immunodeficiency disease that has not been corrected;
  • (3) Accompanied by severe, active, or uncontrolled infectious diseases, including but not limited to active tuberculosis, latent tuberculous infection, active viral hepatitis, etc.;
  • (4) Known to have active malignant diseases or confirmed malignancies before screening (including hematological malignancies and solid tumors, except for resected and cured cutaneous basal cell carcinoma);
  • (5) Suffering from congenital heart disease or having a history of acute myocardial infarction within 6 months, or severe arrhythmia (including multifocal frequent ventricular supraventricular tachycardia, ventricular tachycardia, etc.); or complicated with moderate to large pericardial effusion, severe myocarditis, etc.; or unstable vital signs requiring vasopressors to maintain blood pressure;
  • (6) Accompanied by other diseases that require long-term use of glucocorticoids or immunosuppressants;
  • (7) Received solid organ transplantation or hematopoietic stem cell transplantation within 3 months before screening; or presence of acute graft-versus-host disease (GVHD) of grade 2 or above within 2 weeks before screening;
  • (8) Positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) and peripheral blood hepatitis B virus (HBV) DNA titer detection is greater than the normal reference range; or positive for hepatitis C virus (HCV) antibody and peripheral blood hepatitis C virus (HCV) RNA titer detection is greater than the normal reference range; or positive for human immunodeficiency virus (HIV) antibody; or positive for syphilis test;
  • (9) Received live vaccines within 4 weeks before screening;
  • (10) Positive blood pregnancy test;
  • (11) Participated in other clinical trials within 3 months before enrollment;
  • (12) Other conditions that the investigator considers unsuitable for participation in the study.
Chongqing Precision Biotech Co., Ltd logoChongqing Precision Biotech Co., Ltd
Zentrale Studienkontakte
Kontakt: Lu Mei ping, M.D, +86 13685773988, [email protected]
1 Studienstandorte in 1 Ländern

Zhejiang

Children's Hospital Zhejiang University School of Medicine, Hangzhou, zhejiang, Hangzhou, Zhejiang, China
Meiping Lu, M.D, Kontakt, +86 13685773988, [email protected]
Offene Rekrutierung